Becton, Dickinson and Company

Equities

BDX

US0758871091

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 16:00:02 2024-05-03 EDT 5-day change 1st Jan Change
234.7 USD -2.36% Intraday chart for Becton, Dickinson and Company +1.82% -3.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
TD Cowen Adjusts Price Target on Becton, Dickinson and Company to $260 From $271 MT
Evercore ISI Raises Becton, Dickinson and Company Price Target to $282 From $280 MT
Sector Update: Health Care Stocks Mixed Premarket Thursday MT
Sector Update: Health Care MT
Transcript : Becton, Dickinson and Company, Q2 2024 Earnings Call, May 02, 2024
Becton, Dickinson's Fiscal Q2 Adjusted Earnings, Revenue Rise; Fiscal 2024 Outlook Revised MT
Becton Dickinson Shakes Up 2024 Outlook After Growing 2Q Sales, Earnings DJ
(BDX) BD (BECTON DICKINSON AND COMPANY) Expects Fiscal Year 2024 EPS Range $12.95 - $13.15 MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Reports Q2 Revenue $5.05B, vs. Street Est of $5.04B MT
Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Posts Q2 EPS $3.17, vs. Street Est of $2.97 MT
Becton, Dickinson and Company Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024 CI
BD Maintains Quarterly Dividend at $0.95 Per Share; Payable June 28 to Shareholders of Record on June 10 MT
Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024 CI
Becton, Dickinson and Company acquired FlowJo LLC. CI
Becton Dickinson Releases New Image-Enabled Cell Sorters MT
Becton, Dickinson and Company Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters CI
AngioDynamics Settles Patent Dispute with Becton, Dickinson Affiliate MT
AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co DJ
Sector Update: Health Care Stocks Higher in Late Afternoon Trading MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Sector Update: Health Care MT
Becton, Dickinson Raising Domestic Production of Syringes MT
Transcript : Becton, Dickinson and Company Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM
Becton, Dickinson and Co. Enrolls First Person in Trial of Stent to Treat Peripheral Arterial Disease MT
Chart Becton, Dickinson and Company
More charts
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
240.4 USD
Average target price
279 USD
Spread / Average Target
+16.07%
Consensus
  1. Stock Market
  2. Equities
  3. BDX Stock
  4. News Becton, Dickinson and Company
  5. Becton, Dickinson and Co.'s Notes Get Cash Tender Offers Up to $200 Million by Morgan Stanley